• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4598319)   Today's Articles (12)   Subscriber (49354)
Number Citation Analysis
101
Tyulyandina A, Tsimafeyeu I, Demidova I, Gikalo M, Tjulandin S. Abstract 4586: FGFR2 amplification in serous ovarian cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-4586] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
102
Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Khochenkov D, Joose JB, Solomko E, Van Akene K, Peretolchina N, Yin W, Ryabaya O, Byakhov M, Tjulandin S. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. Eur J Cancer 2016;61:20-8. [DOI: 10.1016/j.ejca.2016.03.068] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Revised: 01/24/2016] [Accepted: 03/17/2016] [Indexed: 12/18/2022]
103
Dudko E, Chernov V, Bogush T, Dyakova Y, Kirsanov V, Shprakh Z, Kamensky A, Polotsky B, Tjulandin S, Shestakova E. Digoxin is a modifier increasing platinum drug anticancer activity. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61482-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
104
Fedyanin M, Polyanskaya E, Sekhina O, Tryakin A, Tjulandin S. P-049 A population study of correlation between the treatment rate for monoclonal antibodies (Mabs) and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.47] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
105
Ignatova E, Frolova M, Stenina MB, Petrovsky A, Tjulandin S. Induction chemotherapy for patients with Locally advanced triple negative breast cancer. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e12573] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]  Open
106
Fedyanin M, Tryakin A, Bulanov A, Sekhina O, Pokataev I, Polockii B, Zakharova T, Garin A, Tjulandin S. Chemotherapy efficacy and prognosis of patients with mediastinal seminoma. Single institution experience. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e16053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
107
Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AV, Thomas A, Tjulandin S, Guan X, Price TJ. Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.3538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
108
Fedyanin M, Stroganova A, Senderovich A, Dranko S, Tryakin A, Pokataev I, Polyanskaya E, Gordeev S, Rasulov A, Polyakov A, Sagaydak I, Tjulandin S. Concordance of KRAS, NRAS, BRAF, PIK3CA mutation status in the primary tumor (PT) and metachronous metastases in patients (pts) with colorectal cancer (CRC). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e15026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
109
Price TJ, Kim TW, Li J, Cascinu S, Ruff P, Suresh AV, Thomas A, Tjulandin S, Guan X, Peeters M. Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e15050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
110
Frolova M, Ignatova E, Stenina MB, Petrovsky A, Tjulandin S. Role of different germline BRCA mutations in response to platinum-based chemotherapy in patients (pts) with triple-negative breast cancer (TNBC). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e13008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
111
Tryakin A, Pokataev I, Kononets P, Fedyanin M, Bokhyan V, Malikhova O, Minin K, Shogenov M, Stilidi I, Vybarava A, Davydov M, Tjulandin S. Preoperative chemotherapy in patients with resectable esophageal carcinoma: a single center Phase II study. Jpn J Clin Oncol 2016;46:610-4. [PMID: 27052115 DOI: 10.1093/jjco/hyw039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Accepted: 03/03/2016] [Indexed: 11/12/2022]  Open
112
Han B, Ratcliffe M, Haddad V, Brown H, Tjulandin S, Hagiwara K, Reck M, Normanno N. 59PD Association of EGFR mutation subtypes with clinical and demographic characteristics of patients (pts) with aNSCLC: IGNITE and ASSESS pooled analysis. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30172-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
113
Normanno N, Brown H, Haddad V, Ratcliffe M, McCormack R, Tjulandin S, Hagiwara K, Han B, Reck M. 580_PR: Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experience. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30323-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
114
Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AV, Thomas A, Tjulandin S, Guan X, Hoang T, Hei YJ, Price TJ. Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.4_suppl.519] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
115
Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AV, Thomas A, Tjulandin S, Guan X, Hoang T, Hei YJ, Price TJ. Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.4_suppl.507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
116
Tsimafeyeu I, Byakhov M, Bencetić Mihaljević V, Padovan J, Murillo G, Tjulandin S. Abstract B146: Preclinical pharmacokinetic studies of RPT835, an allosteric FGFR2 inhibitor. Mol Cancer Ther 2015. [DOI: 10.1158/1535-7163.targ-15-b146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
117
Han B, Shi C, Wang M, He Y, Zhang Y, Tjulandin S, Ratcliffe M, McCormack R. 422PD Local diagnostic practices for advanced non-small-cell lung cancer (NSCLC) in Chinese Patients: subset of the IGNITE study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv532.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
118
Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol 2015;34:1034-42. [PMID: 26598744 DOI: 10.1200/jco.2015.62.1797] [Citation(s) in RCA: 272] [Impact Index Per Article: 30.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]  Open
119
Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol 2015;21:11621-35. [PMID: 26556991 PMCID: PMC4631965 DOI: 10.3748/wjg.v21.i41.11621] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Revised: 08/14/2015] [Accepted: 09/30/2015] [Indexed: 02/06/2023]  Open
120
Dudko E, Kaliuzhny S, Bogush T, Tjulandina A, Grishanina A, Kirsanov V, Tjulandin S. 2707 Quantitative immunofluorescent detection of RRM1 protein in ovarian cancer tissue by flow cytometry. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31474-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
121
Tjulandin S, Imyanitov E, Moiseyenko V, Ponomarenko D, Gurina L, Koroleva I, Karaseva V. Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung. Curr Med Res Opin 2015;31:1117-27. [PMID: 25867537 DOI: 10.1185/03007995.2015.1036015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
122
Filon O, Nechaeva M, Burdaeva O, Vladimirov VI, Lifirenko I, Kovalenko NV, Kopp MV, Matrosova M, Mukhametsina G, Panchenko S, Skopin P, Stroyakovskiy D, Krivorotko P, Shapovalova J, Jelvakova I, Sheveleva L, Abrosimova A, Ivanov R, Tjulandin S. Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e20735] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
123
Tryakin A, Fedyanin M, Sergeev U, Bulanov A, Ahmedov B, Zakharova T, Mitin A, Fainstein I, Garin A, Tjulandin S. Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): Efficacy results of phase II trial. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e15566] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
124
Filon O, Orlov S, Burdaeva O, Kopp MV, Kotiv B, Alekseev S, Pecheniy A, Stroyakovskiy D, Gladkov O, Khorinko A, Matrosova M, Galiulin R, Skopin P, Mukhametsina G, Odarchenko S, Kulik S, Kulyaba J, Adamchuk G, Vinnyk Y, Tjulandin S. Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: Results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.8057] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
125
Cunningham D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe MA, Baker N, Oliner KS, Zhang Y, Hoang T, Sidhu R, Catenacci DVT. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.4000] [Citation(s) in RCA: 77] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
PrevPage 5 of 10 12456910Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA